Cogent Biosciences (COGT)
(Delayed Data from NSDQ)
$7.56 USD
-0.36 (-4.55%)
Updated May 10, 2024 04:00 PM ET
After-Market: $7.55 -0.01 (-0.13%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Brokerage Reports
Cogent Biosciences, Inc. [COGT]
Reports for Purchase
Showing records 1 - 20 ( 120 total )
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
After a Disappointing Showing at ASH, Bezuclastinib Shows Signs of Promise Again; 2023 Financials; Raising PT to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Bezuclastinib Currently in "Show Me" Position; Lowering PT to $13
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Bezu Falls from the SUMMIT; Downgrade to Neutral
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Workout at SABCS; Main Event at ASH
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for COGT 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
APEX and SUMMIT Data Presentations at ASH; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
ASH 2023 Abstract Round Up for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- 2023 Small Molecule Precision Oncology Review and Outlook
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Data CGT4859 Presented; Competitive Landscape Updates; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
EORTC-NCI-AACR 2023: Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Cogent Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 SUMMIT and APEX Data in 2H23; 2Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R